je.st
news
Mercks Investigational Grass Sublingual Allergy Immunotherapy Tablet Significantly Reduced Allergy Symptoms and Need for Symptom-Relief Medication in Adults and Children in Pivotal Phase III Study
2013-11-09 18:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. Data to be Presented at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data for its investigational Timothy grass sublingual allergy immunotherapy tablet (MK-7243) from a study involving 1,501 North American adult and pediatric patients. Language: English Contact: For MerckMedia:Pam Eisele, 908-423-5042orRobert Consalvo, 908-423-6595orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: study
iii
children
reduced
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||
|
|||